Does Kesimpta Carry Risks for Hepatitis B History?
Kesimpta (ofatumumab), an anti-CD20 monoclonal antibody for relapsing multiple sclerosis, poses significant risks for people with a history of hepatitis B virus (HBV) infection. The prescribing information warns of HBV reactivation, which can lead to fulminant hepatitis, hepatic failure, and death.[1]
Before starting Kesimpta, test all patients for HBV infection using HBsAg and anti-HBc antibodies. For those with evidence of prior HBV (such as positive anti-HBc), consult a liver specialist. Screen HBV DNA levels if indicated, and monitor closely during and after treatment—monthly for at least 6 months post-discontinuation if HBV DNA is detectable.[1]
What Triggers HBV Reactivation with Kesimpta?
Anti-CD20 therapies like Kesimpta deplete B-cells, impairing immune control over latent HBV. Reactivation occurs in carriers or those with resolved infection (HBsAg-negative, anti-HBc-positive). Postmarketing reports show fatal cases in patients with prior HBV, even years after resolution.[1][2]
How Common Is This Risk?
Clinical trials excluded HBV carriers, so exact rates are unknown. However, similar anti-CD20 drugs (e.g., rituximab) show reactivation in 20-50% of at-risk patients without prophylaxis, with 5-10% mortality in severe cases. Kesimpta carries a boxed warning mirroring these risks.[1][3]
Can Antiviral Prophylaxis Prevent Issues?
Prophylactic antivirals (e.g., entecavir or tenofovir) are recommended for HBsAg-positive patients or those with detectable HBV DNA. Start before Kesimpta and continue 12 months after. For resolved HBV, monitor without routine prophylaxis unless high risk, but decisions are individualized.[1]
What If You've Had Hepatitis B Before?
Avoid Kesimpta if active HBV exists—treat HBV first. For resolved cases, proceed only after specialist review and monitoring. Discontinue immediately if reactivation signs appear (e.g., elevated liver enzymes, jaundice).[1]
Alternatives for MS Patients with HBV History?
Ocrevus (ocrelizumab, another anti-CD20) has identical HBV warnings. Interferon-beta or glatiramer acetate may be safer, lacking B-cell depletion. Discuss with a neurologist; no MS drug is risk-free for HBV carriers.[2][3]
[1] Novartis Kesimpta Prescribing Information
[2] FDA Drug Safety Communication on HBV Reactivation
[3] Clinical Trials Data via PubMed